Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
This report offers an overview of the market trends, drivers, and barriers with respect to the China Treatment Resistant Depression market. It also provides a detailed overview of the market of different regions across North China, Central China, South China, East China, Northeast China, Southwest China, Northwest China. The report deep analyzes type and application in China Treatment Resistant Depression market. Detailed analysis of key players, along with key growth strategies adopted by Treatment Resistant Depression industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.
By Player:
Axsome Therapeutics
Relmada Therapeutics
Allergan
VistaGen Therapeutics
Eli Lilly and Company
ACADIA Pharmaceuticals
Relmada Therapeutics/Minerva Neurosciences
Johnson & Johnson
Celon Pharma
Alkermes
COMPASS Pathways
Allergan/Gedeon Richter's
Johnson & Johnson/Minerva Neurosciences
By Type:
Selective Serotonin Reuptake Inhibitors
Monoamine Oxidase Inhibitors
Tricyclic Antidepressant
Esketamine Nasal Spray
By End-User:
Hospitals
Clinics
Others
By Region:
-
North China
-
Central China
-
South China
-
East China
-
Northeast China
-
Southwest China
-
Northwest China
TABLE OF CONTENT
1 Report Overview
-
1.1 Product Definition and Scope
-
1.2 PEST (Political, Economic, Social and Technological) Analysis of Treatment Resistant Depression Market
-
1.3 Market Segment by Type
-
1.3.1 China Treatment Resistant Depression Market Size and Growth Rate of Selective Serotonin Reuptake Inhibitors from 2016 to 2027
-
1.3.2 China Treatment Resistant Depression Market Size and Growth Rate of Monoamine Oxidase Inhibitors from 2016 to 2027
-
1.3.3 China Treatment Resistant Depression Market Size and Growth Rate of Tricyclic Antidepressant from 2016 to 2027
-
1.3.4 China Treatment Resistant Depression Market Size and Growth Rate of Esketamine Nasal Spray from 2016 to 2027
-
1.4 Market Segment by Application
-
1.4.1 China Treatment Resistant Depression Market Size and Growth Rate of Hospitals from 2016 to 2027
-
1.4.2 China Treatment Resistant Depression Market Size and Growth Rate of Clinics from 2016 to 2027
-
1.4.3 China Treatment Resistant Depression Market Size and Growth Rate of Others from 2016 to 2027
-
1.5 Market Segment by Regions
-
1.5.1 North China Treatment Resistant Depression Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.2 Central China Treatment Resistant Depression Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.3 South China Treatment Resistant Depression Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.4 East China Treatment Resistant Depression Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.5 Northeast China Treatment Resistant Depression Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.6 Southwest China Treatment Resistant Depression Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.7 Northwest China Treatment Resistant Depression Consumption Market Size and Growth Rate from 2016 to 2027
2 Market Trends and Competitive Landscape
-
2.1 Market Trends and Dynamics
-
2.1.1 Market Challenges and Restraints
-
2.1.2 Market Opportunities and Potentials
-
2.1.3 Mergers and Acquisitions
-
2.2 Competitive Landscape Analysis
-
2.2.1 Industrial Concentration Analysis
-
2.2.2 Porter's Five Forces Analysis of the Industry
-
2.2.3 SWOT Analysis for New Entrants
-
2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry
3 Segmentation of Treatment Resistant Depression Market by Types
-
3.1 Products Development Trends of Different Types
-
3.2 Commercial Products Types of Major Vendors
-
3.3 Competitive Landscape Analysis of Different Types
-
3.4 Market Size of Treatment Resistant Depression by Major Types
-
3.4.1 Market Size and Growth Rate of Selective Serotonin Reuptake Inhibitors
-
3.4.2 Market Size and Growth Rate of Monoamine Oxidase Inhibitors
-
3.4.3 Market Size and Growth Rate of Tricyclic Antidepressant
-
3.4.4 Market Size and Growth Rate of Esketamine Nasal Spray
4 Segmentation of Treatment Resistant Depression Market by End-Users
-
4.1 Downstream Client Analysis by End-Users
-
4.2 Competitive Landscape Analysis of Different End-Users
-
4.3 Market Potential Analysis of Different End-Users
-
4.4 Market Size of Treatment Resistant Depression by Major End-Users
-
4.4.1 Market Size and Growth Rate of Treatment Resistant Depression in Hospitals
-
4.4.2 Market Size and Growth Rate of Treatment Resistant Depression in Clinics
-
4.4.3 Market Size and Growth Rate of Treatment Resistant Depression in Others
5 Market Analysis by Regions
-
5.1 China Treatment Resistant Depression Production Analysis by Regions
-
5.2 China Treatment Resistant Depression Consumption Analysis by Regions
-
5.3 Coronavirus (COVID-19) Impact on China Economy
6 North China Treatment Resistant Depression Landscape Analysis
-
6.1 North China Treatment Resistant Depression Landscape Analysis by Major Types
-
6.2 North China Treatment Resistant Depression Landscape Analysis by Major End-Users
7 Central China Treatment Resistant Depression Landscape Analysis
-
7.1 Central China Treatment Resistant Depression Landscape Analysis by Major Types
-
7.2 Central China Treatment Resistant Depression Landscape Analysis by Major End-Users
8 South China Treatment Resistant Depression Landscape Analysis
-
8.1 South China Treatment Resistant Depression Landscape Analysis by Major Types
-
8.2 South China Treatment Resistant Depression Landscape Analysis by Major End-Users
9 East China Treatment Resistant Depression Landscape Analysis
-
9.1 East China Treatment Resistant Depression Landscape Analysis by Major Types
-
9.2 East China Treatment Resistant Depression Landscape Analysis by Major End-Users
10 Northeast China Treatment Resistant Depression Landscape Analysis
-
10.1 Northeast China Treatment Resistant Depression Landscape Analysis by Major Types
-
10.2 Northeast China Treatment Resistant Depression Landscape Analysis by Major End-Users
11 Southwest China Treatment Resistant Depression Landscape Analysis
-
11.1 Southwest China Treatment Resistant Depression Landscape Analysis by Major Types
-
11.2 Southwest China Treatment Resistant Depression Landscape Analysis by Major End-Users
12 Northwest China Treatment Resistant Depression Landscape Analysis
-
12.1 Northwest China Treatment Resistant Depression Landscape Analysis by Major Types
-
12.2 Northwest China Treatment Resistant Depression Landscape Analysis by Major End-Users
13 Major Players Profiles
-
13.1 Axsome Therapeutics
-
13.1.1 Axsome Therapeutics Company Profile and Recent Development
-
13.1.2 Market Performance
-
13.1.3 Product and Service Introduction
-
13.2 Relmada Therapeutics
-
13.2.1 Relmada Therapeutics Company Profile and Recent Development
-
13.2.2 Market Performance
-
13.2.3 Product and Service Introduction
-
13.3 Allergan
-
13.3.1 Allergan Company Profile and Recent Development
-
13.3.2 Market Performance
-
13.3.3 Product and Service Introduction
-
13.4 VistaGen Therapeutics
-
13.4.1 VistaGen Therapeutics Company Profile and Recent Development
-
13.4.2 Market Performance
-
13.4.3 Product and Service Introduction
-
13.5 Eli Lilly and Company
-
13.5.1 Eli Lilly and Company Company Profile and Recent Development
-
13.5.2 Market Performance
-
13.5.3 Product and Service Introduction
-
13.6 ACADIA Pharmaceuticals
-
13.6.1 ACADIA Pharmaceuticals Company Profile and Recent Development
-
13.6.2 Market Performance
-
13.6.3 Product and Service Introduction
-
13.7 Relmada Therapeutics/Minerva Neurosciences
-
13.7.1 Relmada Therapeutics/Minerva Neurosciences Company Profile and Recent Development
-
13.7.2 Market Performance
-
13.7.3 Product and Service Introduction
-
13.8 Johnson & Johnson
-
13.8.1 Johnson & Johnson Company Profile and Recent Development
-
13.8.2 Market Performance
-
13.8.3 Product and Service Introduction
-
13.9 Celon Pharma
-
13.9.1 Celon Pharma Company Profile and Recent Development
-
13.9.2 Market Performance
-
13.9.3 Product and Service Introduction
-
13.10 Alkermes
-
13.10.1 Alkermes Company Profile and Recent Development
-
13.10.2 Market Performance
-
13.10.3 Product and Service Introduction
-
13.11 COMPASS Pathways
-
13.11.1 COMPASS Pathways Company Profile and Recent Development
-
13.11.2 Market Performance
-
13.11.3 Product and Service Introduction
-
13.12 Allergan/Gedeon Richter's
-
13.12.1 Allergan/Gedeon Richter's Company Profile and Recent Development
-
13.12.2 Market Performance
-
13.12.3 Product and Service Introduction
-
13.13 Johnson & Johnson/Minerva Neurosciences
-
13.13.1 Johnson & Johnson/Minerva Neurosciences Company Profile and Recent Development
-
13.13.2 Market Performance
-
13.13.3 Product and Service Introduction
The List of Tables and Figures
-
Figure Product Picture
-
Figure China Treatment Resistant Depression Market Size and Growth Rate of Selective Serotonin Reuptake Inhibitors from 2016 to 2027
-
Figure China Treatment Resistant Depression Market Size and Growth Rate of Monoamine Oxidase Inhibitors from 2016 to 2027
-
Figure China Treatment Resistant Depression Market Size and Growth Rate of Tricyclic Antidepressant from 2016 to 2027
-
Figure China Treatment Resistant Depression Market Size and Growth Rate of Esketamine Nasal Spray from 2016 to 2027
-
Figure Market Share by Type in 2016
-
Figure Market Share by Type in 2021
-
Figure Market Share by Type in 2027
-
Figure China Treatment Resistant Depression Market Size and Growth Rate of Hospitals from 2016 to 2027
-
Figure China Treatment Resistant Depression Market Size and Growth Rate of Clinics from 2016 to 2027
-
Figure China Treatment Resistant Depression Market Size and Growth Rate of Others from 2016 to 2027
-
Figure Market Share by End-User in 2016
-
Figure Market Share by End-User in 2021
-
Figure Market Share by End-User in 2027
-
Figure North China Treatment Resistant Depression Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Central China Treatment Resistant Depression Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure South China Treatment Resistant Depression Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure East China Treatment Resistant Depression Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northeast China Treatment Resistant Depression Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Southwest China Treatment Resistant Depression Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northwest China Treatment Resistant Depression Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Development Trends and Industry Dynamics of Treatment Resistant Depression Industry
-
Figure Market Challenges and Restraints
-
Figure Market Opportunities and Potentials
-
Table Mergers and Acquisition
-
Figure Market Share of TOP 3 Players in 2020
-
Figure Market Share of TOP 5 Players in 2021
-
Figure Market Share of TOP 6 Players from 2016 to 2021
-
Figure Porter's Five Forces Analysis
-
Figure New Entrant SWOT Analysis
-
Figure Coronavirus (COVID-19) Map of China
-
Table Coronavirus (COVID-19) Impact on the Industry
-
Figure Specifications of Different Types of Treatment Resistant Depression
-
Figure Development Trends of Different Types
-
Table Commercial Products Types of Major Vendors
-
Figure Competitive Landscape Analysis of Different Types
-
Table Consumption of Treatment Resistant Depression by Different Types from 2016 to 2027
-
Table Consumption Share of Treatment Resistant Depression by Different Types from 2016 to 2027
-
Figure Market Size and Growth Rate of Selective Serotonin Reuptake Inhibitors
-
Figure Market Size and Growth Rate of Monoamine Oxidase Inhibitors
-
Figure Market Size and Growth Rate of Tricyclic Antidepressant
-
Figure Market Size and Growth Rate of Esketamine Nasal Spray
-
Table Downstream Client Analysis by End-Users
-
Figure Competitive Landscape Analysis of Different End-Users
-
Table Market Potential Analysis of Different End-Users
-
Figure Consumption of Treatment Resistant Depression by Different End-Users from 2016 to 2027
-
Table Consumption Share of Treatment Resistant Depression by Different End-Users from 2016 to 2027
-
Figure Market Size and Growth Rate of Hospitals
-
Figure Market Size and Growth Rate of Clinics
-
Figure Market Size and Growth Rate of Others
-
Table China Treatment Resistant Depression Production by Regions
-
Table China Treatment Resistant Depression Production Share by Regions
-
Figure China Treatment Resistant Depression Production Share by Regions in 2016
-
Figure China Treatment Resistant Depression Production Share by Regions in 2021
-
Figure China Treatment Resistant Depression Production Share by Regions in 2027
-
Table China Treatment Resistant Depression Consumption by Regions
-
Table China Treatment Resistant Depression Consumption Share by Regions
-
Figure China Treatment Resistant Depression Consumption Share by Regions in 2016
-
Figure China Treatment Resistant Depression Consumption Share by Regions in 2021
-
Figure China Treatment Resistant Depression Consumption Share by Regions in 2027
-
Table North China Treatment Resistant Depression Consumption by Types from 2016 to 2027
-
Table North China Treatment Resistant Depression Consumption Share by Types from 2016 to 2027
-
Figure North China Treatment Resistant Depression Consumption Share by Types in 2016
-
Figure North China Treatment Resistant Depression Consumption Share by Types in 2021
-
Figure North China Treatment Resistant Depression Consumption Share by Types in 2027
-
Table North China Treatment Resistant Depression Consumption by End-Users from 2016 to 2027
-
Table North China Treatment Resistant Depression Consumption Share by End-Users from 2016 to 2027
-
Figure North China Treatment Resistant Depression Consumption Share by End-Users in 2016
-
Figure North China Treatment Resistant Depression Consumption Share by End-Users in 2021
-
Figure North China Treatment Resistant Depression Consumption Share by End-Users in 2027
-
Table Central China Treatment Resistant Depression Consumption by Types from 2016 to 2027
-
Table Central China Treatment Resistant Depression Consumption Share by Types from 2016 to 2027
-
Figure Central China Treatment Resistant Depression Consumption Share by Types in 2016
-
Figure Central China Treatment Resistant Depression Consumption Share by Types in 2021
-
Figure Central China Treatment Resistant Depression Consumption Share by Types in 2027
-
Table Central China Treatment Resistant Depression Consumption by End-Users from 2016 to 2027
-
Table Central China Treatment Resistant Depression Consumption Share by End-Users from 2016 to 2027
-
Figure Central China Treatment Resistant Depression Consumption Share by End-Users in 2016
-
Figure Central China Treatment Resistant Depression Consumption Share by End-Users in 2021
-
Figure Central China Treatment Resistant Depression Consumption Share by End-Users in 2027
-
Table South China Treatment Resistant Depression Consumption by Types from 2016 to 2027
-
Table South China Treatment Resistant Depression Consumption Share by Types from 2016 to 2027
-
Figure South China Treatment Resistant Depression Consumption Share by Types in 2016
-
Figure South China Treatment Resistant Depression Consumption Share by Types in 2021
-
Figure South China Treatment Resistant Depression Consumption Share by Types in 2027
-
Table South China Treatment Resistant Depression Consumption by End-Users from 2016 to 2027
-
Table South China Treatment Resistant Depression Consumption Share by End-Users from 2016 to 2027
-
Figure South China Treatment Resistant Depression Consumption Share by End-Users in 2016
-
Figure South China Treatment Resistant Depression Consumption Share by End-Users in 2021
-
Figure South China Treatment Resistant Depression Consumption Share by End-Users in 2027
-
Table East China Treatment Resistant Depression Consumption by Types from 2016 to 2027
-
Table East China Treatment Resistant Depression Consumption Share by Types from 2016 to 2027
-
Figure East China Treatment Resistant Depression Consumption Share by Types in 2016
-
Figure East China Treatment Resistant Depression Consumption Share by Types in 2021
-
Figure East China Treatment Resistant Depression Consumption Share by Types in 2027
-
Table East China Treatment Resistant Depression Consumption by End-Users from 2016 to 2027
-
Table East China Treatment Resistant Depression Consumption Share by End-Users from 2016 to 2027
-
Figure East China Treatment Resistant Depression Consumption Share by End-Users in 2016
-
Figure East China Treatment Resistant Depression Consumption Share by End-Users in 2021
-
Figure East China Treatment Resistant Depression Consumption Share by End-Users in 2027
-
Table Northeast China Treatment Resistant Depression Consumption by Types from 2016 to 2027
-
Table Northeast China Treatment Resistant Depression Consumption Share by Types from 2016 to 2027
-
Figure Northeast China Treatment Resistant Depression Consumption Share by Types in 2016
-
Figure Northeast China Treatment Resistant Depression Consumption Share by Types in 2021
-
Figure Northeast China Treatment Resistant Depression Consumption Share by Types in 2027
-
Table Northeast China Treatment Resistant Depression Consumption by End-Users from 2016 to 2027
-
Table Northeast China Treatment Resistant Depression Consumption Share by End-Users from 2016 to 2027
-
Figure Northeast China Treatment Resistant Depression Consumption Share by End-Users in 2016
-
Figure Northeast China Treatment Resistant Depression Consumption Share by End-Users in 2021
-
Figure Northeast China Treatment Resistant Depression Consumption Share by End-Users in 2027
-
Table Southwest China Treatment Resistant Depression Consumption by Types from 2016 to 2027
-
Table Southwest China Treatment Resistant Depression Consumption Share by Types from 2016 to 2027
-
Figure Southwest China Treatment Resistant Depression Consumption Share by Types in 2016
-
Figure Southwest China Treatment Resistant Depression Consumption Share by Types in 2021
-
Figure Southwest China Treatment Resistant Depression Consumption Share by Types in 2027
-
Table Southwest China Treatment Resistant Depression Consumption by End-Users from 2016 to 2027
-
Table Southwest China Treatment Resistant Depression Consumption Share by End-Users from 2016 to 2027
-
Figure Southwest China Treatment Resistant Depression Consumption Share by End-Users in 2016
-
Figure Southwest China Treatment Resistant Depression Consumption Share by End-Users in 2021
-
Figure Southwest China Treatment Resistant Depression Consumption Share by End-Users in 2027
-
Table Northwest China Treatment Resistant Depression Consumption by Types from 2016 to 2027
-
Table Northwest China Treatment Resistant Depression Consumption Share by Types from 2016 to 2027
-
Figure Northwest China Treatment Resistant Depression Consumption Share by Types in 2016
-
Figure Northwest China Treatment Resistant Depression Consumption Share by Types in 2021
-
Figure Northwest China Treatment Resistant Depression Consumption Share by Types in 2027
-
Table Northwest China Treatment Resistant Depression Consumption by End-Users from 2016 to 2027
-
Table Northwest China Treatment Resistant Depression Consumption Share by End-Users from 2016 to 2027
-
Figure Northwest China Treatment Resistant Depression Consumption Share by End-Users in 2016
-
Figure Northwest China Treatment Resistant Depression Consumption Share by End-Users in 2021
-
Figure Northwest China Treatment Resistant Depression Consumption Share by End-Users in 2027
-
Table Company Profile and Development Status of Axsome Therapeutics
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Axsome Therapeutics
-
Figure Sales and Growth Rate Analysis of Axsome Therapeutics
-
Figure Revenue and Market Share Analysis of Axsome Therapeutics
-
Table Product and Service Introduction of Axsome Therapeutics
-
Table Company Profile and Development Status of Relmada Therapeutics
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Relmada Therapeutics
-
Figure Sales and Growth Rate Analysis of Relmada Therapeutics
-
Figure Revenue and Market Share Analysis of Relmada Therapeutics
-
Table Product and Service Introduction of Relmada Therapeutics
-
Table Company Profile and Development Status of Allergan
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Allergan
-
Figure Sales and Growth Rate Analysis of Allergan
-
Figure Revenue and Market Share Analysis of Allergan
-
Table Product and Service Introduction of Allergan
-
Table Company Profile and Development Status of VistaGen Therapeutics
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of VistaGen Therapeutics
-
Figure Sales and Growth Rate Analysis of VistaGen Therapeutics
-
Figure Revenue and Market Share Analysis of VistaGen Therapeutics
-
Table Product and Service Introduction of VistaGen Therapeutics
-
Table Company Profile and Development Status of Eli Lilly and Company
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eli Lilly and Company
-
Figure Sales and Growth Rate Analysis of Eli Lilly and Company
-
Figure Revenue and Market Share Analysis of Eli Lilly and Company
-
Table Product and Service Introduction of Eli Lilly and Company
-
Table Company Profile and Development Status of ACADIA Pharmaceuticals
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of ACADIA Pharmaceuticals
-
Figure Sales and Growth Rate Analysis of ACADIA Pharmaceuticals
-
Figure Revenue and Market Share Analysis of ACADIA Pharmaceuticals
-
Table Product and Service Introduction of ACADIA Pharmaceuticals
-
Table Company Profile and Development Status of Relmada Therapeutics/Minerva Neurosciences
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Relmada Therapeutics/Minerva Neurosciences
-
Figure Sales and Growth Rate Analysis of Relmada Therapeutics/Minerva Neurosciences
-
Figure Revenue and Market Share Analysis of Relmada Therapeutics/Minerva Neurosciences
-
Table Product and Service Introduction of Relmada Therapeutics/Minerva Neurosciences
-
Table Company Profile and Development Status of Johnson & Johnson
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Johnson & Johnson
-
Figure Sales and Growth Rate Analysis of Johnson & Johnson
-
Figure Revenue and Market Share Analysis of Johnson & Johnson
-
Table Product and Service Introduction of Johnson & Johnson
-
Table Company Profile and Development Status of Celon Pharma
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Celon Pharma
-
Figure Sales and Growth Rate Analysis of Celon Pharma
-
Figure Revenue and Market Share Analysis of Celon Pharma
-
Table Product and Service Introduction of Celon Pharma
-
Table Company Profile and Development Status of Alkermes
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Alkermes
-
Figure Sales and Growth Rate Analysis of Alkermes
-
Figure Revenue and Market Share Analysis of Alkermes
-
Table Product and Service Introduction of Alkermes
-
Table Company Profile and Development Status of COMPASS Pathways
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of COMPASS Pathways
-
Figure Sales and Growth Rate Analysis of COMPASS Pathways
-
Figure Revenue and Market Share Analysis of COMPASS Pathways
-
Table Product and Service Introduction of COMPASS Pathways
-
Table Company Profile and Development Status of Allergan/Gedeon Richter's
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Allergan/Gedeon Richter's
-
Figure Sales and Growth Rate Analysis of Allergan/Gedeon Richter's
-
Figure Revenue and Market Share Analysis of Allergan/Gedeon Richter's
-
Table Product and Service Introduction of Allergan/Gedeon Richter's
-
Table Company Profile and Development Status of Johnson & Johnson/Minerva Neurosciences
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Johnson & Johnson/Minerva Neurosciences
-
Figure Sales and Growth Rate Analysis of Johnson & Johnson/Minerva Neurosciences
-
Figure Revenue and Market Share Analysis of Johnson & Johnson/Minerva Neurosciences
-
Table Product and Service Introduction of Johnson & Johnson/Minerva Neurosciences
-
